| Peter C. Chi, Medical Corporation | |
|
5828 Temple City Blvd Temple City CA 91780-2112 | |
| (626) 285-1154 | |
| (626) 285-1361 |
| Full Name | Peter C. Chi, Medical Corporation |
|---|---|
| Speciality | Family Medicine |
| Location | 5828 Temple City Blvd, Temple City, California |
| Authorized Official Name and Position | Peter C Chi (PRESIDENT) |
| Authorized Official Contact | 6262851154 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Peter C. Chi, Medical Corporation 5828 Temple City Blvd Temple City CA 91780-2112 Ph: (626) 285-1154 | Peter C. Chi, Medical Corporation 5828 Temple City Blvd Temple City CA 91780-2112 Ph: (626) 285-1154 |
| NPI Number | 1912135567 |
|---|---|
| Provider Enumeration Date | 06/22/2009 |
| Last Update Date | 02/11/2011 |
| Medicare PECOS PAC ID | 1153473335 |
|---|---|
| Medicare Enrollment ID | O20090720000090 |
News Archive
Traditional treatment of movement problems for people who have suffered traumatic brain injury or strokes has mainly focused on making the best use of motor functions the patient has retained.
Mystic Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of advanced precision ophthalmic and intranasal delivery technologies for drugs and biologics, today announced that it has been awarded a non-taxable grant of approximately $245,000 related to its VersiDoser™ Delivery Platform under the Qualifying Therapeutic Discovery Project (QTDP) program included in the Patient Protection and Affordable Health Care Act of 2010.
NIH Acting Director Raynard Kington on Thursday during a House Appropriations Labor-HHS-Education Subcommittee hearing said that the agency might use some of the $10.4 billion it received from the economic stimulus package to fund comparative effectiveness research that includes comparisons on the cost of treatments, CQ HealthBeat reports.
Heart attack, or myocardial infarction, is the number one cause of death worldwide. A study published in the European Heart Journal by scientists at Helmholtz Zentrum München and colleagues from a range of other Bavarian institutions shows that the risk of suffering a heat-induced heart attack has increased significantly in recent years.
For the first time, researchers have followed the development of blood vessels in zebrafish embryos without using any labels or contrast agents, which may disturb the biological processes under study.
› Verified 2 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912135567 | NPI | - | NPPES |
| F72123 | Other | CA | UPIN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | G77088 (California) | Primary |
| Provider Name | Peter C Chi |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1023090867 PECOS PAC ID: 9638254386 Enrollment ID: I20090720000079 |
News Archive
Traditional treatment of movement problems for people who have suffered traumatic brain injury or strokes has mainly focused on making the best use of motor functions the patient has retained.
Mystic Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of advanced precision ophthalmic and intranasal delivery technologies for drugs and biologics, today announced that it has been awarded a non-taxable grant of approximately $245,000 related to its VersiDoser™ Delivery Platform under the Qualifying Therapeutic Discovery Project (QTDP) program included in the Patient Protection and Affordable Health Care Act of 2010.
NIH Acting Director Raynard Kington on Thursday during a House Appropriations Labor-HHS-Education Subcommittee hearing said that the agency might use some of the $10.4 billion it received from the economic stimulus package to fund comparative effectiveness research that includes comparisons on the cost of treatments, CQ HealthBeat reports.
Heart attack, or myocardial infarction, is the number one cause of death worldwide. A study published in the European Heart Journal by scientists at Helmholtz Zentrum München and colleagues from a range of other Bavarian institutions shows that the risk of suffering a heat-induced heart attack has increased significantly in recent years.
For the first time, researchers have followed the development of blood vessels in zebrafish embryos without using any labels or contrast agents, which may disturb the biological processes under study.
› Verified 2 days ago
News Archive
Traditional treatment of movement problems for people who have suffered traumatic brain injury or strokes has mainly focused on making the best use of motor functions the patient has retained.
Mystic Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of advanced precision ophthalmic and intranasal delivery technologies for drugs and biologics, today announced that it has been awarded a non-taxable grant of approximately $245,000 related to its VersiDoser™ Delivery Platform under the Qualifying Therapeutic Discovery Project (QTDP) program included in the Patient Protection and Affordable Health Care Act of 2010.
NIH Acting Director Raynard Kington on Thursday during a House Appropriations Labor-HHS-Education Subcommittee hearing said that the agency might use some of the $10.4 billion it received from the economic stimulus package to fund comparative effectiveness research that includes comparisons on the cost of treatments, CQ HealthBeat reports.
Heart attack, or myocardial infarction, is the number one cause of death worldwide. A study published in the European Heart Journal by scientists at Helmholtz Zentrum München and colleagues from a range of other Bavarian institutions shows that the risk of suffering a heat-induced heart attack has increased significantly in recent years.
For the first time, researchers have followed the development of blood vessels in zebrafish embryos without using any labels or contrast agents, which may disturb the biological processes under study.
› Verified 2 days ago
Ovi Moas M D A Professional Corporation Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 9815 Las Tunas Dr, Temple City, CA 91780 Phone: 626-285-7158 Fax: 626-285-9392 | |
Franck Juste Md Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 9676 Las Tunas Dr, Temple City, CA 91780 Phone: 626-287-6513 Fax: 626-287-6497 | |
Kevin T. Lee, M.d., A Professional Corporation Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 5801 Rosemead Blvd, Temple City, CA 91780 Phone: 626-292-1241 Fax: 626-292-1746 | |
Gaby J. Abdo, D.o., A Medical Corp. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 5546 Rosemead Blvd, Suite 207, Temple City, CA 91780 Phone: 626-433-7253 Fax: 626-782-6263 | |
Arete Family Medicine Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 5807 Temple City Blvd, Temple City, CA 91780 Phone: 626-872-0082 Fax: 626-872-0081 | |
Health Care Partners Medical Group Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 9810 Las Tunas Dr, Temple City, CA 91780 Phone: 626-309-7601 Fax: 626-309-9345 |